Emmaus Life Sciences, Inc. (EMMA)
Emmaus Life Sciences, Inc.
21250 Hawthorne Boulevard
Suite 800
Torrance, CA 90503
United States
310 214 0065
https://www.emmausmedical.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 54
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Willis C. Lee M.S. | Co-President, COO & Chairman of the Board | 240k | N/D | 1960 |
| Mr. Yasushi Nagasaki CPA, CPA | Chief Financial Officer | 250k | N/D | 1967 |
| Mr. George Sekulich | Co-President, Chief Commercial Officer & Director | N/D | N/D | 1966 |
| Mr. Dale E. Short J.D. | Legal Consultant & Corporate Secretary | N/D | N/D | N/D |
| Dr. Charles W. Stark Pharm.D, Pharm.D. | Senior Vice President of Medical Affairs, Clinical, Regulatory | N/D | N/D | 1955 |
| Mr. Kurt H. Kruger M.B.A., M.S. | Consultant | 300.02k | N/D | 1955 |
Descripción
Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. The company was founded in 2000 and is headquartered in Torrance, California.
Gestión corporativa
La calificación ISS Governance QuickScore de Emmaus Life Sciences, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
